First Online: 12 October 2018
: P.D.L. is a non-paid member of the scientific advisory board of FirstString Research and has been granted stock options (currently no value) for his service. D.W.L. received a small 1-year grant from Zealand Pharma in 2016 to test potential pannexin 1-modulating peptides.